RecruitingNCT05122403

Multimodal MRI for MRgFUS Central Lateral Thalamotomy in Neuropathic Pain

Multimodal Magnetic Resonance Imaging Study for Magnetic Resonance-Guided Focused Ultrasound Central Lateral Thalamotomy in Neuropathic Pain


Sponsor

Chinese PLA General Hospital

Enrollment

12 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

To explore the pathogenesis underlying neuropathic pain as well as the mechanisms of pain relief after Magnetic resonance-guided focused ultrasound (MRgFUS) Central Lateral Thalamotomy through multi-model MRI study, and to identify imaging biomarkers for triaging patients and predicting the clinical outcomes. Craniofacial neuropathic pain is one of the most serious debilitating symptoms, leading to emotional disorders and poor quality of life. Previous studies have shown that Magnetic resonance-guided focused ultrasound (MRgFUS) central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients. However, the clinical benefits were variable among individuals. It is important to clarify the pathogenesis of neuropathic pain and the mechanisms of pain relief induced by MRgFUS central lateral thalamotomy to triage suitable candidates for the procedure and predict clinical outcomes. In addition, localization precision and individualized treatment remain to be improved.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Male and female, aged between 18 and 75 (inclusive);
  • Subjects who are able and willing to participate in the study;
  • Chronic neuropathic pain with disease duration lasting more than 6 months;
  • The worst NPRS score was ≥ 5 (out of 10), and the subjects reported a similar degree of pain in at least the past two months;
  • Medication-refractory neuropathic pain with resistance to at least three kinds of neuropathic pain prescription drugs and one interventional procedure

Exclusion Criteria10

  • Craniofacial pain syndrome associated with malignant tumors of the head and neck;
  • Idiopathic trigeminal neuralgia;
  • Headache syndrome, such as migraine;
  • Temporomandibular joint syndrome;
  • Atypical facial pain or pain related to somatoform disorders;
  • Subjects are regarded as unqualified candidates by experts;
  • active mental illness;
  • unstable heart state;
  • severe hypertension (diastolic blood pressure after taking medicine >100mm/Hg)
  • MR imaging standard contraindications, such as non-MRI compatible implanted metal devices, including pacemakers.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMRgFUS central lateral thalamotomy

MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.


Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05122403


Related Trials